Cytokinetics’ muscle gambit nears POC for next-gen therapies

Cytokinetics is banking that its nearly 15 years of muscle biology research will pay dividends with its next-generation therapies for cardiovascular and neuromuscular disorders. The next signal will come in early May when the biotech reports Phase II data for reldesemtiv in ALS.

Over its 21 year history -- the first six of which were spent in cancer -- Cytokinetics Inc. has seen its share of wins and losses. ...